HEMORGANIC share price & results
- Sept 2026
- Sept 2026
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.4 | Quarterly, as filed | Quarter to Sept 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | 0.7 | Operating profit / revenue | Quarter to Sept 2026 | For the quarter; a change is in percentage points. | |
| Net profit | 0.01 | Quarterly, as filed | Quarter to Sept 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | -22.39 | +136.5 pts | Trailing twelve months | TTM to Sept 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | Fiscal year | FY ending Mar 2026 | Not in the analysed materials. No older figure is substituted. | ||
| Revenue growth (YoY) | -2.07 | +38.6 pts | Trailing twelve months | TTM to Sept 2026 | Revenue change against the same period one year earlier. |
Price
Performance +159.8% 1Y
1Y: ₹8.41 on 24 Oct 2025 → ₹21.85. High ₹24.42 (14 Jul 2026), low ₹8.31 (30 Oct 2025).
- Previous close
- ₹22.97
- Market cap
- ₹5 Cr
- 52-week range
- ₹8.31 – ₹24.42
- One year
- +162.30%
- Return on equity (TTM to Sept 2026)
- -22.39%
Overview
- Symbol
- NSE:HEMORGANIC
- Exchange
- NSE
- Currency
- INR
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +133% (quarter to sept 2026 against sept 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
| Expenses | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
| Operating profit | -0 | 0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Operating margin | — | 6.2% | — | — | — | −32.3% | — | 0.7% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | 0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Tax rate | 0.0% | −58.3% | −27.3% | −25.0% | 220.0% | 70.0% | 0.0% | 0.0% |
| Net profit | -0 | 0 | -0 | -0 | -0 | -1 | -0 | 0 |
| EPS (₹ per share) | -0.23 | 1.07 | -0.26 | -0.09 | -0.46 | -1.47 | -0.20 | 0.03 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 0 | 2 | 1 |
| Expenses | 0 | 2 | 1 |
| Operating profit | -0 | -0 | -0 |
| Other income | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | -0 | 0 | -0 |
| Net profit | -0 | 0 | -1 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 7 |
| Reserves | -4 | -4 | -4 | -4 | -3 | -4 |
| Borrowings | 0 | 1 | 1 | 2 | 3 | 1 |
| Other liabilities | 0 | 0 | 4 | 4 | 2 | 0 |
| Total liabilities | 0 | 1 | 5 | 5 | 4 | 5 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 0 | 1 | 5 | 5 | 4 | 5 |
| Total assets | 0 | 1 | 5 | 5 | 4 | 5 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -0 | 0 | 0 | -1 | -0 | -1 |
| Cash from investing | 0 | 0 | 0 | 0 | 0 | -1 |
| Cash from financing | 0 | 0 | 0 | 1 | 0 | 2 |
| Net cash flow | -0 | 0 | 0 | 0 | -0 | 0 |
| Free cash flow | -0 | 0 | 0 | -1 | -0 | -1 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 2555 | 2190 | — | 1460 | 382 | 938 |
| Inventory days | 0 | 730 | — | — | 143 | — |
| Days payable | — | 4015 | — | — | 366 | — |
| Cash conversion cycle | 2555 | -1095 | — | 1460 | 159 | 938 |
| Working capital days | -1825 | -4015 | — | 11863 | 156 | 1122 |
| Return on capital employed | −43.5% | −75.0% | −250.0% | −52.2% | 2.6% | −23.8% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 97.49% as of Sept 2026.
- Promoters 2.50%
- Public 97.49%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 24.76% held
- newly disclosed 24.76% held
- newly disclosed 2.27% held
- newly disclosed 2.27% held
- newly disclosed 1.62% held
- +0.26 pp 1.84% held
The same filing shows 6 holders trimming and 8 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of HEMORGANIC above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 24.76% | newly disclosed | |
| 24.76% | newly disclosed | |
| 2.40% | −13.09 pp | |
| 2.27% | newly disclosed | |
| 2.27% | newly disclosed | |
| 1.84% | +0.26 pp | |
| 1.76% | −1.73 pp | |
| 1.76% | −1.73 pp | |
| 1.62% | newly disclosed | |
| 1.27% | −1.24 pp | |
| 1.00% | −1.11 pp | |
| 0.10% | −1.26 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for HEMORGANIC
Free account: one company. Everything above stays public.
Write why you follow HEMORGANIC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Learn to analyse HEMORGANIC
Guides on how to read this kind of business and the numbers that matter.